Johnson & Johnson's first-quarter earnings will give investors their first look at how Actelion will impact the company. These ETFs could benefit if investors like what they hear.
Johnson & Johnson is undergoing a transformation in its product portfolio. These three ETFs may be worth buying.
Pharma stocks have bounced back from their prior selloff, but whether they will continue their upward trend under a Donald Trump administration remains unclear.
The health care sector's ties to the increasingly unpopular Affordable Care Act, plus an uncertain U.S. presidential picture, give some financial experts pause.
Johnson & Johnson is undergoing a transformation in its product portfolio. These three ETFs may benefit if investors are excited about third-quarter results.